Non-neurogenic overactive bladder
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patient has non-neurogenic overactive bladder. 2) Written informd consent is required. 3) One or more times a week of urge urinary incontinence was seen after antichorinergic drugs or antichorinergic drugs could not be continued because of adverse effects.
Exclusion criteria
Exclusion criteria: 1) The patient has apparent neurogenic diseases causing urinary tract symptoms. 2) The patient underwent treatment with botulinum toxin A. 3) The patient underwent the surgery of lower urinary tract within 1 year. 4) Postvoid residual urine is 100ml or greater. 5) The patient has apparent lower urinary tract obstruction and/or weak detrusor. 6) Average voiding volume are 200ml or greater on frequency-volume chart. 7) The patient has stress urinary incontinence and/or functional urinary incontinence. 8) The patient has active urinary tract infection, malignance and/or bladder stone. 9) The patient is pregnant or breast-feed, or have possibility of such matter within 1 year. 10) The patient is diagnosed as having myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis. 11) The patient has disturbance of swallowing and/or respiration. 12) The patitent has mental and/or cognitive disturbance to conduct the clinical trial. 13) The patient is judged as being unsuitable for the trial by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the number of urge urinary incontinence 1month after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence of urge urinary incontinence, change of bladder capacity and symptoms after treatment | — |
Countries
Japan
Contacts
National Center for Geriatrics & Gerontology Division of Urology, Department of Surgery & Intensive Care